GLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering?

摘要

The treatment of type 2 diabetes (T2D) focuses on glycemic control to reduce microvascular and macro-vascular complications. Unfortunately, while pivotal studies using conventional therapies have demonstrated that intensive glycemic control positively impacts microvascular complications, effects on cardiovascular benefit are less robust (1). There is therefore intense interest in newer antidiabetes agents, such as glucagon-like peptide 1 receptor (GLP-1R) agonists, which lower blood glucose and modify cardiovascular risk factors (lipids, adiposity, blood pressure) without increasing hypoglycemic risk (2). Whether GLP-1R agonists improve endothelial dysfunction is less clear, but this potential effect is important as endothelial dysfunction increases the risk for cardiovascular events in T2D (3).